More biotech bubble chatter; Celladon nears make-or-break data dump;

@FierceBiotech: Cellectis upscales IPO toward $200M as CAR-T fever continues. Report | Follow @FierceBiotech

@JohnCFierce: ICYMI: Not giving up day job, but interviewing @Asthika from Bloomberg Intelligence on biotech market was fun. Watch | Follow @JohnCFierce

@DamianFierce: Last night's Jeopardy question about CAR-T means this is definitely a bubble, right? | Follow @DamianFierce

> The Wall Street Journal is the latest to take up the "is this a biotech bubble?" issue, pointing to sky-high valuations and quoting analysts worried that the market is getting too frothy. Gawker, meanwhile, preaches patience, assuring readers that "Everything will be fine, as long as none of these experimental drugs fail." WSJ story (sub. req.) | Gawker post

> Celladon Therapeutics ($CLDN) forthcoming data readout on its heart treatment could be the next big catalyst for gene therapy's so-called renaissance, Adam Feuerstein writes. More

Medical Device News

@FierceMedDev: French cancer Dx company born after management buyout at Qiagen unit. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Does the FDA overregulate devices? Experts weigh in. More | Follow @VarunSaxena2

@EmilyWFierce: Cepheid got FDA emergency use authorization for its rapid Ebola test. Release | Follow @EmilyWFierce

> Novartis rides med tech wave with new digital projects. Item

> Pennsylvania surgical tools manufacturing plant scheduled for closure, 250 layoffs planned. Article

Pharma News

@FiercePharma: Why All Those Testosterone Ads Constitute Disease Mongering. Forbes article | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Former Boehringer Ingelheim workers whiplashed by China firm's plans for Virginia API plant. Article | Follow @EricPFierce

@CarlyHFierce: Which diseases are driving drug spending hikes? It's not just hep C. Story | Follow @CarlyHFierce

> Geriatrics experts call for halt to Low-T consumer ads. More

> The $600 million man: Gilead CEO's stock gains push compensation way past estimates. Article

Biotech Research News

> Concert Pharma spotlights a positive rat study for antiseizure drug. Report

> Duke/NUS team says new combo has promise for mutant-RAS cancers. More

> CMV-based vaccine could help eliminate the threat of Ebola from apes. Story

> Stem cell advance may assist new therapies for anemia, leukemia. Item

> Targeted mitochondrial attack destroys glioma cells in preclinical study. Article

Diagnostics News

> Foundation Medicine reveals C-suite and board metamorphosis. Article

> French cancer Dx company born after management buyout at Qiagen unit. Story

> GE Healthcare's pathology arm to use Omnyx's software for digital analysis of specimens. More

> Dako strikes another cancer companion Dx deal with Amgen. Item

> Roche joins forces with Sigma-Aldrich to distribute biochemical reagents. Article

Pharma Marketing News

> Psoriasis data wars heat up at AAD with Novartis, Boehringer studies. Article

> Were Low-T ads 'disease mongering'? Two experts say yes. Story

> The 2014 DTC ads that made the grade. More

> Pharma's ad spend vaults to $4.5B, with big spender Pfizer leading the way. Article

> Sanofi aims for that sweet smell of success with spring Nasacort campaign. Report

Suggested Articles

The action will see Kiadis switch its attention to earlier-stage natural killer cell therapies against solid tumors and hematological cancers.

The Weill Family Foundation is stumping up $106 million to create a so-called “Neurohub.”

The takeover centers on TRPML1 agonists designed to treat neurodegenerative disorders by clearing toxic proteins from the brain.